Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

The prognosis for patients with recurrent glioblastomas (GBMs) is dismal, with a median survival of 3–6 months. We performed a phase II trial of low-dose continuous (metronomic) treatment using temozolomide (TMZ) for recurrent GBMs. TMZ-refractory patients with GBM who experienced disease recurrence...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kong, Doo-Sik, Lee, Jung-Il, Kim, Jong Hyun, Kim, Sung Tae, Kim, Won Seog, Suh, Yeon-Lim, Dong, Seung Myung, Nam, Do-Hyun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2010
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940595/
https://ncbi.nlm.nih.gov/pubmed/20167817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop030
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller